Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Tyrosine kinase inhibitors (TKIs) are widely used to treat various solid tumors; however, adverse events, such as fatigue and anorexia, remain significant concerns. TKI-induced primary adrenal insufficiency (PAI) is a potential cause of these symptoms; however, its pathophysiology remains ...
Accurate survival prediction is essential for guiding follow-up strategies in patients with cT1b renal cell carcinoma (RCC). Traditional AJCC TNM staging systems provide limited prognostic accuracy. Data from the SEER database were used, which included 22,426 patients with cT1b RCC who ...
Patients with intermediate- to high-risk resectable ccRCC who had not received immunosuppressive agents were randomized in a 1:1:1 ratio to receive 2 ...
Profiling of renal medullary carcinoma highlights TROP2 and Hippo signaling as key vulnerabilities, supporting new therapeutic strategies.
Background Renal cell carcinoma (RCC) accounts for 90% of all renal neoplasms and is often incidentally detected through unrelated imaging procedures. Differentiating between benign and malignant renal masses remains challenging using imaging alone. Urinary biomarkers may aid in this ...
Background Renal cell carcinoma (RCC) accounts for 90% of all renal neoplasms and is often incidentally detected through unrelated imaging procedures. Differentiating between benign and malignant renal masses remains challenging using imaging alone. Urinary biomarkers may aid in this ...
A groundbreaking study from the University of Michigan Health Rogel Cancer Center and its Department of Pathology sheds new light on the diagnosis of renal cell carcinoma (RCC), specifically the
The incidence and mortality of kidney cancer vary widely globally. This study aims to examine the global burden and trends of kidney cancer from 1990 to 2021 and its associations with various factors. Data on kidney cancer cases and age-standardized rates (ASRs) of incidence, prevalence, ...
Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a Phase 3 clinical trial titled ‘A Randomized, Doub...
Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma ...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.